Cargando…

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights

Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient populati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Starr, Jason S, Sonbol, Mohamad Bassam, Hobday, Timothy J, Sharma, Akash, Kendi, Ayse Tuba, Halfdanarson, Thorvardur R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205451/ https://www.ncbi.nlm.nih.gov/pubmed/32431509 http://dx.doi.org/10.2147/OTT.S202867

Ejemplares similares

Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis
por: Sonbol, Mohamad Bassam, et al.
Publicado: (2022)

Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy
por: Halfdanarson, Thorvardur R., et al.
Publicado: (2023)

Intracranial neuroendocrine tumour simulating meningioma for several years: an overview of diagnosis and treatment
por: Badawy, Mohamed, et al.
Publicado: (2022)

Targeted Alpha-Particle Therapy: A Review of Current Trials
por: Jang, Albert, et al.
Publicado: (2023)

Primary neuroendocrine carcinoma of the brain
por: Reed, Clay T, et al.
Publicado: (2019)

Pilot Study Characterizing the Hematology-Oncology Fellow Job Search Process: Tools Used and Identification of Potential New Resources
por: Marshall, Ariela L., et al.
Publicado: (2021)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

Constrictive bronchiolitis in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
por: Samhouri, Bilal F., et al.
Publicado: (2020)

Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases
por: Ngongoni, Rejoice, et al.
Publicado: (2022)

Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors
por: Gudmundsdottir, Hallbera, et al.
Publicado: (2022)

Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States
por: Shah, Shrunjal, et al.
Publicado: (2021)

The Quality of Online Information for an Uncommon Malignancy—Neuroendocrine Tumours (NETs)
por: Sohail, Safa, et al.
Publicado: (2021)

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
por: Lim, Lisi Elizabeth, et al.
Publicado: (2020)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021)

Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report
por: Kumar, Amit, et al.
Publicado: (2022)

A Care Process Model to Deliver (177)Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2019)

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
por: Saberzadeh-Ardestani, Bahar, et al.
Publicado: (2023)

Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies
por: Diamantopoulos, Leonidas N., et al.
Publicado: (2023)

Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
por: Kucukyurt, Selin, et al.
Publicado: (2020)

Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
por: Asbach, Stefan, et al.
Publicado: (2017)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

Twitter Use by Academic Nuclear Medicine Programs: Pilot Content Analysis Study
por: Panda, Ananya, et al.
Publicado: (2021)

Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study
por: Fazio, Nicola, et al.
Publicado: (2021)

Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)

The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature
por: Montanier, Nathanaëlle, et al.
Publicado: (2017)

SUN-914 Peptide Receptor Radionuclide Therapy for an Inoperable Small Cell Neuroendocrine Tumor in the Philippines
por: Alegria, Rainier Mark Gabriel
Publicado: (2020)

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
por: Liberini, Virginia, et al.
Publicado: (2020)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
por: Camus, Baptiste, et al.
Publicado: (2021)

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
por: Opalińska, Marta, et al.
Publicado: (2021)

Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy
por: Hendifar, Andrew E., et al.
Publicado: (2022)

Treatment of Neuroendocrine Tumor Liver Metastases
por: Lewis, Mark A., et al.
Publicado: (2012)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
por: Yordanova, Anna, et al.
Publicado: (2020)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
por: Severi, Stefano, et al.
Publicado: (2017)

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
por: Huizing, Daphne Merel Valerie, et al.
Publicado: (2018)

Radiation precautions for inpatient and outpatient (177)Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
por: Levart, D., et al.
Publicado: (2019)

Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
por: Kipnis, Sarit T., et al.
Publicado: (2021)

Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors
por: Hasegawa, Sho, et al.
Publicado: (2022)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2bgcar92731idp4j4s53p76ns5